Kura Oncology (KURA) – Analysts’ Recent Ratings Changes

Kura Oncology (NASDAQ: KURA) has recently received a number of price target changes and ratings updates:

• 8/24/2026 – Kura Oncology was given a new $24.00 price target by Raymond James Financial, Inc..
• 8/24/2026 – Kura Oncology was given a new $24.00 price target by Morgan Stanley.
• 8/24/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/24/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $24.00 price target on the stock.
• 8/13/2026 – Kura Oncology had its price target raised by Wedbush from $36.00 to $38.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – Kura Oncology had its “outperform” rating reaffirmed by Wedbush. They now have a $36.00 price target on the stock.
• 7/17/2026 – Kura Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, CEO Troy Edward Wilson bought 100,000 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were acquired at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the purchase, the chief executive officer directly owned 479,194 shares in the company, valued at $5,937,213.66. The trade was a 26.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brian T. Powl sold 4,345 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the completion of the transaction, the insider directly owned 169,269 shares of the company’s stock, valued at $2,012,608.41. This trade represents a 2.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 120,761 shares of company stock worth $1,283,346. Corporate insiders own 7.60% of the company’s stock.

Get Kura Oncology Inc alerts:

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

See Also

• Five stocks we like better than Kura Oncology
• Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
• Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
• Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
• Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Kura Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.